NCT06871644 - Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions

Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Interventions

BIOLOGICAL

T cell injection targeting CD7 chimeric antigen receptor

Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of

Trial Locations (1)

230088

PersonGen.Anke Cellular Therapeutice Co. Ltd, Hefei